Jeffrey Cummings

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi request reprint Dementia with lewy bodies: molecular pathogenesis and implications for classification
    Jeffrey L Cummings
    Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    J Geriatr Psychiatry Neurol 17:112-9. 2004
  2. doi request reprint Defining and labeling disease-modifying treatments for Alzheimer's disease
    Jeffrey L Cummings
    Mary S Easton Center for Alzheimer s Disease Research at UCLA, Departments of Neurology and Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Alzheimers Dement 5:406-18. 2009
  3. doi request reprint Effect of donepezil on cognition in severe Alzheimer's disease: a pooled data analysis
    Jeffrey Cummings
    Cleveland Clinic, Lou Ruvo Center for Brain Health, Las Vegas, NV, USA
    J Alzheimers Dis 21:843-51. 2010
  4. pmc Controversies in Alzheimer's disease drug development
    Jeffrey L Cummings
    Departments of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Int Rev Psychiatry 20:389-95. 2008
  5. doi request reprint Optimizing phase II of drug development for disease-modifying compounds
    Jeffrey L Cummings
    Department of Neurology and Psychiatry, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Alzheimers Dement 4:S15-20. 2008
  6. doi request reprint Behavioral effects of current Alzheimer's disease treatments: a descriptive review
    Jeffrey L Cummings
    UCLA Alzheimer Disease Center, UCLA, Los Angeles, CA, USA
    Alzheimers Dement 4:49-60. 2008
  7. ncbi request reprint ADCS Prevention Instrument Project: behavioral measures in primary prevention trials
    Jeffrey L Cummings
    Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 1769, USA
    Alzheimer Dis Assoc Disord 20:S147-51. 2006
  8. ncbi request reprint A rivastigmine patch for the treatment of Alzheimer's disease and Parkinson's disease dementia
    Jeffrey Cummings
    UCLA Alzheimer s Center, 10911 Weyburn Avenue, Suite 200, Los Angeles, CA 90095 7226, USA
    Expert Rev Neurother 7:1457-63. 2007
  9. ncbi request reprint Fluctuations in cognitive function in dementia with Lewy bodies
    Jeffrey L Cummings
    David Geffen School of Medicine, UCLA, Los Angeles, CA, USA
    Lancet Neurol 3:266. 2004
  10. ncbi request reprint Pharmacokinetic rationale for the rivastigmine patch
    Jeffrey Cummings
    UCLA Alzheimer s Center, Los Angeles, CA 90095 7226, USA
    Neurology 69:S10-3. 2007

Detail Information

Publications98

  1. ncbi request reprint Dementia with lewy bodies: molecular pathogenesis and implications for classification
    Jeffrey L Cummings
    Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    J Geriatr Psychiatry Neurol 17:112-9. 2004
    ..Classification systems based on symptom complexes related to the presence of protein misfolding will assist therapeutic decisions...
  2. doi request reprint Defining and labeling disease-modifying treatments for Alzheimer's disease
    Jeffrey L Cummings
    Mary S Easton Center for Alzheimer s Disease Research at UCLA, Departments of Neurology and Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Alzheimers Dement 5:406-18. 2009
    ..Prevention claims will depend heavily on biomarker outcomes...
  3. doi request reprint Effect of donepezil on cognition in severe Alzheimer's disease: a pooled data analysis
    Jeffrey Cummings
    Cleveland Clinic, Lou Ruvo Center for Brain Health, Las Vegas, NV, USA
    J Alzheimers Dis 21:843-51. 2010
    ..The treatment effect size and correlation between improvements in SIB scores and functional and global outcome measures suggest the drug-placebo differences are clinically meaningful...
  4. pmc Controversies in Alzheimer's disease drug development
    Jeffrey L Cummings
    Departments of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Int Rev Psychiatry 20:389-95. 2008
    ..The questions surrounding these issues must be resolved as disease-modifying therapies for AD are advanced. These controversies are framed and potential directions towards resolution described...
  5. doi request reprint Optimizing phase II of drug development for disease-modifying compounds
    Jeffrey L Cummings
    Department of Neurology and Psychiatry, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Alzheimers Dement 4:S15-20. 2008
    ..been validated in a successful drug development program; all have some promise for reforming phase II and answering the central question of "how much information is sufficient to proceed to phase III without excessive risk for failure?"..
  6. doi request reprint Behavioral effects of current Alzheimer's disease treatments: a descriptive review
    Jeffrey L Cummings
    UCLA Alzheimer Disease Center, UCLA, Los Angeles, CA, USA
    Alzheimers Dement 4:49-60. 2008
    ....
  7. ncbi request reprint ADCS Prevention Instrument Project: behavioral measures in primary prevention trials
    Jeffrey L Cummings
    Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 1769, USA
    Alzheimer Dis Assoc Disord 20:S147-51. 2006
    ..Experimental behavioral measures were included in the protocol to examine this hypothesis...
  8. ncbi request reprint A rivastigmine patch for the treatment of Alzheimer's disease and Parkinson's disease dementia
    Jeffrey Cummings
    UCLA Alzheimer s Center, 10911 Weyburn Avenue, Suite 200, Los Angeles, CA 90095 7226, USA
    Expert Rev Neurother 7:1457-63. 2007
    ..Treatment differences on the Neuropsychiatric Inventory and Ten Point Clock-drawing Test did not reach statistical significance in this study. The patch may be the optimal way to treat dementia patients with rivastigmine...
  9. ncbi request reprint Fluctuations in cognitive function in dementia with Lewy bodies
    Jeffrey L Cummings
    David Geffen School of Medicine, UCLA, Los Angeles, CA, USA
    Lancet Neurol 3:266. 2004
  10. ncbi request reprint Pharmacokinetic rationale for the rivastigmine patch
    Jeffrey Cummings
    UCLA Alzheimer s Center, Los Angeles, CA 90095 7226, USA
    Neurology 69:S10-3. 2007
    ..The potential of a patch to improve the tolerability of rivastigmine (e.g., nausea and vomiting) while permitting similar exposure to the highest doses of capsules may, in turn, lead to improved efficacy and compliance...
  11. ncbi request reprint Disease-modifying therapies for Alzheimer disease: challenges to early intervention
    Jeffrey L Cummings
    Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Neurology 69:1622-34. 2007
    ..The neurologic health of the growing aging population demands disease-modifying therapies and the development of methods to identify and test promising candidate agents...
  12. ncbi request reprint Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment
    Jeffrey L Cummings
    Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 1769, USA
    Neurology 67:57-63. 2006
    ..To investigate the behavioral effects of memantine in moderate to severe Alzheimer disease (AD)...
  13. ncbi request reprint Effects of donepezil on neuropsychiatric symptoms in patients with dementia and severe behavioral disorders
    Jeffrey L Cummings
    Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, California, USA
    Am J Geriatr Psychiatry 14:605-12. 2006
    ..The authors report the effects of donepezil on behavioral disturbances in patients with relatively severe psychopathology at baseline...
  14. ncbi request reprint Treatments for behavioural disorders in neurodegenerative diseases: drug development strategies
    Jeffrey L Cummings
    Department of Neurology, 710 Westwood Plaza, David Geffen School of Medicine, UCLA, Los Angeles, California 90095, USA
    Nat Rev Drug Discov 5:64-74. 2006
    ....
  15. ncbi request reprint Effects of rivastigmine treatment on the neuropsychiatric and behavioral disturbances of nursing home residents with moderate to severe probable Alzheimer's disease: a 26-week, multicenter, open-label study
    Jeffrey L Cummings
    University of California, Los Angeles, Alzheimer s Disease Center, Los Angeles, California 90095 1769, USA
    Am J Geriatr Pharmacother 3:137-48. 2005
    ....
  16. ncbi request reprint Clinical evaluation as a biomarker for Alzheimer's disease
    Jeffrey L Cummings
    Department of Neurology, Alzheimer s Disease Research Center, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 1769, USA
    J Alzheimers Dis 8:327-37. 2005
    ..Biomarkers must closely reflect clinical outcomes to be useful as evaluations of disease progression or as outcomes in clinical trials...
  17. doi request reprint Biomarkers in Alzheimer's disease drug development
    Jeffrey L Cummings
    Cleveland Clinic Lou Ruvo Center for Brain Health, Cleveland Clinic Neurological Institute, Las Vegas, NV, USA
    Alzheimers Dement 7:e13-44. 2011
    ..Fit-for-purpose biomarkers are increasingly available to guide AD drug development decisions...
  18. ncbi request reprint Alzheimer's disease
    Jeffrey L Cummings
    Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 1769, USA
    N Engl J Med 351:56-67. 2004
  19. ncbi request reprint Effects of rivastigmine transdermal patch and capsule on aspects of clinical global impression of change in Alzheimer's disease: a retrospective analysis
    Jeffrey L Cummings
    Mary S Easton Center for Alzheimer s Disease Research at UCLA, Los Angeles, CA 90095 7226, USA
    Dement Geriatr Cogn Disord 29:406-12. 2010
    ..This was a hypothesis-forming study, designed to provide a basis for possible future research...
  20. pmc Integrating ADNI results into Alzheimer's disease drug development programs
    Jeffrey L Cummings
    Mary S Easton Center for Alzheimer s Disease Research at UCLA, Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 7226, United States
    Neurobiol Aging 31:1481-92. 2010
    ....
  21. ncbi request reprint Alzheimer's disease: from molecular biology to neuropsychiatry
    Jeffrey L Cummings
    Department of Neurology and Psychiatry, Reed Neurological Research Center, UCLA School of Medicine, Los Angeles, CA 90095 1769, USA
    Semin Clin Neuropsychiatry 8:31-6. 2003
    ..The steps of the amyloid cascade present multiple targets for drug development and identification of effective disease-modifying anti-Alzheimer's disease treatments...
  22. doi request reprint Effects of rivastigmine in Alzheimer's disease patients with and without hallucinations
    Jeffrey Cummings
    Mary S Easton Center for Alzheimer s Disease Research at UCLA, Los Angeles, CA 90095 7226, USA
    J Alzheimers Dis 20:301-11. 2010
    ..3 points (p< 0.05). Interaction testing suggested that differences in treatment effects were significant between hallucinators and non-hallucinators. Hallucinations predicted greater treatment responses to oral rivastigmine...
  23. doi request reprint Rivastigmine transdermal patch skin tolerability: results of a 1-year clinical trial in patients with mild-to-moderate Alzheimer's disease
    Jeffrey L Cummings
    Mary S Easton Center for Alzheimer s Disease Research at UCLA, 10911 Weyburn Ave, Suite 200, Los Angeles, CA 90095 7226, USA
    Clin Drug Investig 30:41-9. 2010
    ..The aim of the component of the trial reported here was to evaluate the skin tolerability of the rivastigmine transdermal patch in patients with mild-to-moderate AD...
  24. doi request reprint Predicting cognitive decline in Alzheimer's disease: an integrated analysis
    Oscar L Lopez
    Department of Neurology, Alzheimer s Disease Research Center, University of Pittsburgh, Pittsburgh, PA, USA
    Alzheimers Dement 6:431-9. 2010
    ..Numerous patient- and disease-related factors increase the risk of rapid cognitive decline in patients with Alzheimer's disease (AD). The ability of pharmacological treatment to attenuate this risk remains undefined...
  25. ncbi request reprint ADCS Prevention Instrument Project: overview and initial results
    Steven H Ferris
    Alzheimer s Disease Center, New York University School of Medicine, New York, NY 10016, USA
    Alzheimer Dis Assoc Disord 20:S109-23. 2006
    ..Initial results for the experimental instruments and for the book club are reported in separate accompanying articles...
  26. ncbi request reprint Frequency and characteristics of anxiety among patients with Alzheimer's disease and related dementias
    Verna R Porter
    Department of Neurology, University of California, Los Angeles, School of Medicine, USA
    J Neuropsychiatry Clin Neurosci 15:180-6. 2003
    ..These data suggest that anxiety is common among patients with diverse forms of dementia. In AD, anxiety is most common in those with more severe cognitive deterioration and an earlier age at onset...
  27. pmc Symptomatic and nonamyloid/tau based pharmacologic treatment for Alzheimer disease
    Paul S Aisen
    University of California, San Diego, California 92093, USA
    Cold Spring Harb Perspect Med 2:a006395. 2012
    ..We also review putative therapies that aim to slow disease progression by mechanisms not directly related to amyloid or tau...
  28. ncbi request reprint Executive dysfunction in Alzheimer disease
    Margaret M Swanberg
    Department of Neurology, David Geffen School of Medicine at UCLA, 90095 1769, USA
    Arch Neurol 61:556-60. 2004
    ..Executive dysfunction (EDF) is common in Alzheimer disease (AD); however, its relationship to other symptoms is difficult to assess in patients with AD...
  29. ncbi request reprint ADCS Prevention Instrument Project: development of a brief verbal memory test for primary prevention clinical trials
    David P Salmon
    Department of Neurosciences, University of California, San Diego, La Jolla, California 92093 0948, USA
    Alzheimer Dis Assoc Disord 20:S139-46. 2006
    ....
  30. ncbi request reprint Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial
    Jeffrey Cummings
    Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA
    Lancet 383:533-40. 2014
    ..We aimed to assess safety and efficacy of pimavanserin, a selective serotonin 5-HT2A inverse agonist, in this population...
  31. doi request reprint Efficacy of higher dose 13.3 mg/24 h rivastigmine patch on instrumental activities of daily living in patients with mild-to-moderate Alzheimer's disease
    George Grossberg
    Department of Neurology and Psychiatry, St Louis University School of Medicine, St Louis, MO 61304, USA
    Am J Alzheimers Dis Other Demen 28:583-91. 2013
    ..Stabilizing/reducing decline in the ability to perform activities of daily living (ADLs) is important in management of Alzheimer's disease (AD)...
  32. ncbi request reprint Dementia with parkinsonism: what is the diagnosis?
    Mei S Chong
    Department of Neurology, The David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Rev Neurol Dis 1:41-4. 2004
    ..The 72-year-old patient whose case is reviewed here had abnormalities in all three domains...
  33. ncbi request reprint Mild cognitive impairment is associated with characteristic neuropsychiatric symptoms
    Tzung J Hwang
    Department of Neurology, UCLA School of Medicine, Los Angeles, CA 90095 1769, USA
    Alzheimer Dis Assoc Disord 18:17-21. 2004
    ..Psychotic symptoms are significantly more common in the early stage of AD than in MCI. These results are derived from a limited clinical sample and require confirmation in longitudinal community-based investigations...
  34. ncbi request reprint Age and rate of cognitive decline in Alzheimer disease: implications for clinical trials
    Charles Bernick
    Lou Ruvo Center for Brain Health, Cleveland Clinic, Las Vegas, Nevada 89106, USA
    Arch Neurol 69:901-5. 2012
    ..Factors that affect the rate of progression of Alzheimer disease (AD) need to be considered in the clinical trial designs of potential disease-modifying therapies...
  35. ncbi request reprint Efficacy of olanzapine in the treatment of psychosis in dementia with lewy bodies
    Jeffrey L Cummings
    Department of Neurology, UCLA School of Medicine, Los Angeles, Calif, USA
    Dement Geriatr Cogn Disord 13:67-73. 2002
    ..This study sought to determine whether patients with dementia with Lewy bodies (DLB) and psychosis responded to treatment with olanzapine...
  36. ncbi request reprint Early-onset Alzheimer's disease is associated with greater pathologic burden
    Gad A Marshall
    Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, USA
    J Geriatr Psychiatry Neurol 20:29-33. 2007
    ..This suggests that late-onset AD patients have less cognitive reserve than early-onset patients and require fewer pathologic changes to exhibit cognitive deterioration...
  37. ncbi request reprint Neuropathologic correlates of activities of daily living in Alzheimer disease
    Gad A Marshall
    Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095 1769, USA
    Alzheimer Dis Assoc Disord 20:56-9. 2006
    ..Deteriorating activities of daily living in Alzheimer Disease subjects correlate with greater overall pathologic burden and possibly selectively with involvement of the medial temporal, occipital, and orbital frontal regions...
  38. ncbi request reprint Apolipoprotein epsilon4 status is associated with behavioral symptoms in nursing home residents with dementia
    Diana Lynn Woods
    School of Nursing, University of California, Los Angeles 90095 6919, USA
    Int Psychogeriatr 21:722-8. 2009
    ..The aim of this study was to examine the association between APOE genotype and BSD in NH residents using direct observation...
  39. ncbi request reprint Positron emission tomography metabolic correlates of apathy in Alzheimer disease
    Gad A Marshall
    Department of Neurology, University of California, Los Angeles, CA, USA
    Arch Neurol 64:1015-20. 2007
    ....
  40. ncbi request reprint Treatment of Alzheimer's disease: current and future therapeutic approaches
    Jeffrey L Cummings
    Department of Neurology, University of California, The David Geffen School of Medicine, Los Angeles, CA, USA
    Rev Neurol Dis 1:60-9. 2004
    ..Improved methodologies for clinical trial design and analysis and the development of biological markers may hasten the identification of effective treatments for AD...
  41. ncbi request reprint Guidelines for managing Alzheimer's disease: part I. Assessment
    Jeffrey L Cummings
    University of California, Los Angeles, School of Medicine, USA
    Am Fam Physician 65:2263-72. 2002
    ..Suggestions for easily administered and scored assessment tools are provided, and practical tips are given for supporting primary caregivers, thereby increasing efficiency and quality of care for patients with Alzheimer's disease...
  42. doi request reprint Randomized, double-blind, parallel-group, 48-week study for efficacy and safety of a higher-dose rivastigmine patch (15 vs. 10 cm²) in Alzheimer's disease
    Jeffrey Cummings
    Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV 89106, USA
    Dement Geriatr Cogn Disord 33:341-53. 2012
    ..5 mg/24 h (10 cm(2)) rivastigmine patch, benefit from a dose increase in a double-blind (DB) comparative trial of two patch doses...
  43. doi request reprint A modern hypothesis: The distinct pathologies of dementia associated with Parkinson's disease versus Alzheimer's disease
    Martin R Farlow
    Department of Neurology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Dement Geriatr Cogn Disord 25:301-8. 2008
    ..The aim of this review was to survey the recent literature on the pathology of PDD and compare the pathology of PDD to that of Alzheimer's disease (AD)...
  44. pmc Diagnosing depression in Alzheimer disease with the national institute of mental health provisional criteria
    Edmond Teng
    Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90073, USA
    Am J Geriatr Psychiatry 16:469-77. 2008
    ....
  45. ncbi request reprint Creativity and dementia: emerging diagnostic and treatment methods for Alzheimer's disease
    Jeffrey L Cummings
    UCLA Alzheimer s Disease Research Center, University of California, Los Angeles, CA, USA
    CNS Spectr 13:1-20; quiz 22. 2008
    ..Debra Cherry, PhD, discusses the advocacy needs of Alzheimer's disease patients and their caregivers. In addition, Patricia Utermohlen, MA, provides a testimonial of the impact of Alzheimer's disease on an accomplished artist...
  46. ncbi request reprint The prevalence and correlates of neuropsychiatric symptoms in a population with Parkinson's disease in Mexico
    John M Ringman
    Department of Neurology, UC Irvine School of Medicine, Irvine, California, USA
    Neuropsychiatry Neuropsychol Behav Neurol 15:99-105. 2002
    ..To study the incidence of behavioral abnormalities in patients with Parkinson's disease (PD) and extend them to a Mexican population...
  47. ncbi request reprint Treatment of Alzheimer's disease: the role of symptomatic agents in an era of disease-modifying therapies
    Jeffrey L Cummings
    Departmentsof Neurology and Psychiatry, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Rev Neurol Dis 4:57-62. 2007
    ..Therapeutic regimens for the treatment of AD will include both disease-modifying and symptomatic agents...
  48. pmc Association of GSK3B with Alzheimer disease and frontotemporal dementia
    Barbara A J Schaffer
    Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, 2506 Gonda, 695 Charles E Young Dr S, Los Angeles, CA 90095 1761, USA
    Arch Neurol 65:1368-74. 2008
    ..As a known tau kinase, GSK3B is a promising candidate gene in the remaining cases of FTD and in AD, for which tau mutations have not been found...
  49. ncbi request reprint Guidelines for managing Alzheimer's disease: Part II. Treatment
    Jeffrey L Cummings
    University of California, Los Angeles, School of Medicine, USA
    Am Fam Physician 65:2525-34. 2002
    ..Throughout the course of the disease, routine use of community resources allows care to be provided by a network of professionals, many of whom will be specialists in Alzheimer's disease...
  50. ncbi request reprint Functional ability in executive variant Alzheimer's disease and typical Alzheimer's disease
    Carla Back-Madruga
    University of Southern California, Keck School of Medicine, Los Angeles, CA 90033, USA
    Clin Neuropsychol 16:331-40. 2002
    ....
  51. ncbi request reprint Neuropsychiatric symptoms are associated with progression from mild cognitive impairment to Alzheimer's disease
    Edmond Teng
    Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 7226, USA
    Dement Geriatr Cogn Disord 24:253-9. 2007
    ..Depression and apathy may identify a subset of MCI subjects at higher risk of progression to Alzheimer's disease (AD). However, it remains uncertain whether a broader spectrum of psychopathology is associated with progression to AD...
  52. ncbi request reprint Neuropsychiatric manifestations in mild cognitive impairment: a systematic review of the literature
    Liana G Apostolova
    Department of Neurology, David Geffen School of Medicine, UCLA, USA
    Dement Geriatr Cogn Disord 25:115-26. 2008
    ..MCI is an important risk state for dementia. Neuropsychiatric symptoms may be present in MCI...
  53. ncbi request reprint Speech and language in progressive nonfluent aphasia compared with early Alzheimer's disease
    Mario F Mendez
    Department of Neurology, David Geffen School of Medicine, University of California at Los Angeles, USA
    Neurology 61:1108-13. 2003
    ..The differentiation of PA from early Alzheimer's disease (AD) is important, given the presence of early language changes in AD...
  54. pmc Surface feature-guided mapping of cerebral metabolic changes in cognitively normal and mildly impaired elderly
    Liana G Apostolova
    Department of Neurology, David Geffen School of Medicine, University of California Los Angeles, 10911 Weyburn Avenue, Los Angeles, CA 90095, USA
    Mol Imaging Biol 12:218-24. 2010
    ..The aim of this study was to investigate the longitudinal positron emission tomography (PET) metabolic changes in the elderly...
  55. pmc Current concepts of mild cognitive impairment and their applicability to persons at-risk for familial Alzheimer's disease
    John M Ringman
    Mary S Easton Center for Alzheimer s Disease Research at UCLA, Associate Clinical Professor, UCLA Department of Neurology, 10911 Weyburn Ave, 200, Los Angeles, CA 90095 7226, USA
    Curr Alzheimer Res 6:341-6. 2009
    ..The study of FAD provides an opportunity to test various criteria for early AD and these observations should be taken into consideration in future iterations of such diagnostic criteria...
  56. ncbi request reprint Alzheimer disease
    Jeffrey L Cummings
    Department of Neurology, University of California, Los Angeles, School of Medicine, Los Angeles, CA 90095, USA
    JAMA 287:2335-8. 2002
  57. ncbi request reprint Subcortical hyperintensities in Alzheimer's disease: associated clinical and metabolic findings
    David L Sultzer
    Departments of Psychiatry and Biobehavioral Sciences, University of California Los Angeles, USA
    J Neuropsychiatry Clin Neurosci 14:262-9. 2002
    ..These preliminary findings indicate that subcortical MRI hyperintensities may play a role in the pathophysiology and clinical expression of Alzheimer's disease...
  58. pmc Subtle deficits in instrumental activities of daily living in subtypes of mild cognitive impairment
    Edmond Teng
    Neurobehavior Unit, Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, CA 90073, USA
    Dement Geriatr Cogn Disord 30:189-97. 2010
    ..We explored the relationship between these factors by comparing instrumental activities of daily living (IADLs) among cognitive subtypes of MCI and examining associations between IADL and neuropsychological indices...
  59. ncbi request reprint Neuropathologic correlates of apathy in Alzheimer's disease
    Gad A Marshall
    Department of Neurology, University of California at Los Angeles, Reed Neurological Research Center, 2 238, 710 Westwood Plaza, CA 90095 1769, USA
    Dement Geriatr Cogn Disord 21:144-7. 2006
    ..01, and r = 0.438, p = 0.032). This analysis suggests that chronic apathy in AD correlates with a greater anterior cingulate NFT burden and that chronic behavioral changes are more reflective than acute changes of disease pathology...
  60. pmc 3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects
    Liana G Apostolova
    Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA, United States
    Neurobiol Aging 31:1284-303. 2010
    ..p-tau(181) showed stronger correlation in ApoE4 carriers, while t-tau showed stronger correlation in ApoE4 noncarriers. Of the 3 PIB measures the precuneal SUVR showed strongest associations with hippocampal atrophy...
  61. pmc 3D comparison of low, intermediate, and advanced hippocampal atrophy in MCI
    Liana G Apostolova
    Department of Neurology, David Geffen School of Medicine, UCLA, CA, USA
    Hum Brain Mapp 31:786-97. 2010
    ..Greater CA1 and subicular atrophy can be demonstrated early and is predictive of future conversion to AD, whereas CA2-3 involvement becomes more evident as the disease progresses...
  62. pmc Mary S. Easton Center of Alzheimer's Disease Research at UCLA: advancing the therapeutic imperative
    Jeffrey L Cummings
    Department of Neurology, The Mary S Easton Center for Alzheimer s Disease Research at UCLA, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
    J Alzheimers Dis 19:375-88. 2010
    ..The Center supports excellent senior 3 investigators and serves as an incubator for new scientists, agents, models, technologies and concepts that will significantly influence the future of AD treatment and AD research...
  63. pmc Automated 3D mapping of baseline and 12-month associations between three verbal memory measures and hippocampal atrophy in 490 ADNI subjects
    Liana G Apostolova
    Department of Neurology, David Geffen School of Medicine, UCLA, Los Angeles, CA 90095, USA
    Neuroimage 51:488-99. 2010
    ..After controlling for baseline hippocampal atrophy, memory performance showed regionally specific associations with hippocampal radial distance in predominantly CA1 but also in subicular distribution...
  64. ncbi request reprint Relational integration and executive function in Alzheimer's disease
    James A Waltz
    Departjment of Psychology, University of California, Los Angeles, CA 90095 1563, USA
    Neuropsychology 18:296-305. 2004
    ....
  65. ncbi request reprint Heterogeneous age-related breakdown of white matter structural integrity: implications for cortical "disconnection" in aging and Alzheimer's disease
    George Bartzokis
    Department of Neurology, Univeristy of California School of Medicine, Los Angeles, CA 90095, USA
    Neurobiol Aging 25:843-51. 2004
    ..In AD this process is globally exacerbated, consistent with an extracellular deleterious process such as amyloid beta-peptide toxicity. Non-invasive measures such as R2 may be useful in primary prevention studies of AD...
  66. ncbi request reprint 3D mapping of mini-mental state examination performance in clinical and preclinical Alzheimer disease
    Liana G Apostolova
    Department of Neurology, David Geffen School of Medicine, UCLA, Los Angeles, CA 90095, USA
    Alzheimer Dis Assoc Disord 20:224-31. 2006
    ..As a global cognitive measure, MMSE depends on the integrity of widely distributed cortical areas in both brain hemispheres with left-sided predominance...
  67. ncbi request reprint 3D comparison of hippocampal atrophy in amnestic mild cognitive impairment and Alzheimer's disease
    Liana G Apostolova
    Department of Neurology, David Geffen School of Medicine UCLA, CA, USA
    Brain 129:2867-73. 2006
    ..Novel hippocampal analytic techniques that can track the spread of hippocampal pathology in 3D with such precision are a promising research tool...
  68. ncbi request reprint Neuropsychiatric and behavioral symptoms in a community sample of Hispanics with Alzheimer's disease
    Freddy Ortiz
    The Neuropsychiatry Research Memory Clinic, Olive View UCLA Medical Center, Sylmar, CA 91342, USA
    Am J Alzheimers Dis Other Demen 21:263-73. 2006
    ..These findings have implications for differential sociocultural presentations of Alzheimer's disease among ethnic/racial groups...
  69. pmc A potential role of the curry spice curcumin in Alzheimer's disease
    John M Ringman
    University of California, Los Angeles, Department of Neurology, Alzheimer s Disease Research Center, Los Angeles, CA 90095, USA
    Curr Alzheimer Res 2:131-6. 2005
    ..We are therefore performing a study of curcumin in patients with AD to gather this information in addition to data on the effect of curcumin on biomarkers of AD pathology...
  70. ncbi request reprint Regression to the mean: implications for clinical trials of psychotropic agents in dementia
    Jeffrey L Cummings
    Department of Neurology, UCLA School of Medicine, Los Angeles, CA 90095 1769, USA
    Curr Alzheimer Res 1:323-8. 2004
    ..Research design adjustments such as collection of both screening and baseline measures to determine eligibility may limit the effects of regression to the mean on trial outcomes and reduce this challenge to clinical trials...
  71. ncbi request reprint Behavioral and neuropsychiatric outcomes in Alzheimer's disease
    Jeffrey L Cummings
    Alzheimer s Disease Research Center, Department of Neurology, University of California Los Angeles, 710 Westwood Plaza Rm 2 238, Los Angeles, CA 90095, USA
    CNS Spectr 10:22-5. 2005
    ....
  72. ncbi request reprint Effects of testosterone on cognition and mood in male patients with mild Alzheimer disease and healthy elderly men
    Po H Lu
    Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, USA
    Arch Neurol 63:177-85. 2006
    ..There is a compelling need for therapies that prevent, defer the onset, slow the progression, or improve the symptoms of Alzheimer disease (AD)...
  73. ncbi request reprint Apolipoprotein E genotype and age-related myelin breakdown in healthy individuals: implications for cognitive decline and dementia
    George Bartzokis
    Department of Neurology, The David Geffen School of Medicine at UCLA, USA
    Arch Gen Psychiatry 63:63-72. 2006
    ..This may result in a progressive "disconnection" of widely distributed neural networks that may underlie the age risk factor for AD...
  74. ncbi request reprint Deficits in facial emotion processing in mild cognitive impairment
    Edmond Teng
    Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 7226, USA
    Dement Geriatr Cogn Disord 23:271-9. 2007
    ..Patients with Alzheimer disease consistently demonstrate impaired performance on tests of facial emotion processing. However, it remains unclear how early in the neurodegenerative process these deficits emerge...
  75. ncbi request reprint Effective pharmacologic management of Alzheimer's disease
    Martin R Farlow
    Department of Neurology, Indiana University School of Medicine, Indianapolis 46202 5111, USA
    Am J Med 120:388-97. 2007
    ....
  76. pmc Three-dimensional gray matter atrophy mapping in mild cognitive impairment and mild Alzheimer disease
    Liana G Apostolova
    Department of Neurology, David Geffen School of Medicine, University of California at Los Angeles, 10911 Westwood Blvd, Second Floor, Los Angeles, CA 90095, USA
    Arch Neurol 64:1489-95. 2007
    ..Most patients with MCI harbor the pathologic changes of AD and demonstrate transition to dementia at a rate of 10% to 15% per year. Patients with AD and MCI experience progressive brain atrophy...
  77. pmc 3D mapping of language networks in clinical and pre-clinical Alzheimer's disease
    Liana G Apostolova
    Department of Neurology, David Geffen School of Medicine, UCLA, CA, USA
    Brain Lang 104:33-41. 2008
    ..Using a novel 3D mapping technique, we demonstrated that in AD language abilities are strongly influenced by the integrity of the perisylvian cortical regions...
  78. ncbi request reprint The Cleveland Clinic Lou Ruvo Center for Brain Health: keeping memory alive
    Jeffrey Cummings
    Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA
    J Alzheimers Dis 38:103-9. 2014
    ....
  79. ncbi request reprint Performance of a shortened Scale for Assessment of Positive Symptoms for Parkinson's disease psychosis
    Tiffini Voss
    University of Virginia, Department of Neurology, PO Box 800394, Charlottesville, VA, USA
    Parkinsonism Relat Disord 19:295-9. 2013
    ..Parkinson's disease psychosis is a frequent and serious complication of advanced disease, but few disease-specific outcome measures exist...
  80. ncbi request reprint Microtenotomy using a radiofrequency probe to treat lateral epicondylitis
    James P Tasto
    San Diego Sports Medicine and Orthopedic Center, University of California, San Diego, La Jolla, California, USA
    Arthroscopy 21:851-60. 2005
    ..To evaluate the safety and effectiveness of microtenotomy using a radiofrequency (RF) probe to treat chronic tendinosis of the common extensor tendon origins of the elbow (lateral epicondyle)...
  81. doi request reprint Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect
    Erik P Pioro
    Section of ALS and Related Disorders, Department of Neurology, Neurological Institute, Cleveland Clinic, Cleveland, OH 44195, USA
    Ann Neurol 68:693-702. 2010
    ..To evaluate dextromethorphan combined with ultra low-dose quinidine (DMq) for treating pseudobulbar affect (PBA) in patients with amyotrophic lateral sclerosis (ALS) or multiple sclerosis (MS)...
  82. pmc Globalization of Alzheimer's disease clinical trials
    Jeffrey Cummings
    Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, Nevada 89106, USA
    Alzheimers Res Ther 3:24. 2011
    ..Attention to these potential influences on clinical trials will determine the success of global drug development programs and the utility of global trials for developing new AD therapeutics...
  83. ncbi request reprint Executive control function: a review of its promise and challenges for clinical research. A report from the Committee on Research of the American Neuropsychiatric Association
    Donald R Royall
    The University of Texas Health Science Center, 7703 Floyd Curl Drive, San Antonio, TX 78229 3900, USA
    J Neuropsychiatry Clin Neurosci 14:377-405. 2002
    ..The prevalence and severity of ECF deficits in many disorders remain to be determined, and treatment has been attempted in only a few disorders. Much more research in these areas is necessary...
  84. ncbi request reprint Prevalence and impact of medical comorbidity in Alzheimer's disease
    P Murali Doraiswamy
    Department of Psychiatry, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Gerontol A Biol Sci Med Sci 57:M173-7. 2002
    ..We examined the prevalence of comorbid medical illnesses in Alzheimer's disease (AD) patients at different severity levels. We also examined the effect of cumulative medical comorbidity on cognition and function...
  85. ncbi request reprint Searching for methods to detect, prevent, and treat Alzheimer's disease
    Jeffrey L Cummings
    Am J Psychiatry 162:645-7. 2005
  86. ncbi request reprint The impact of depressive symptoms on patients with Alzheimer disease
    Jeffrey L Cummings
    Alzheimer Dis Assoc Disord 17:61-2. 2003
  87. ncbi request reprint Executive dysfunction and apathy predict functional impairment in Alzheimer disease
    Patricia A Boyle
    Brown Medical School, Providence, RI, USA
    Am J Geriatr Psychiatry 11:214-21. 2003
    ..The purpose of this study was to examine the extent to which executive cognitive dysfunction and frontally-mediated behavioral disturbances are associated with functional impairment in patients with mild-to-moderate Alzheimer disease (AD)...
  88. ncbi request reprint Measuring disease modification in Alzheimer's disease
    Jeffrey L Cummings
    CNS Spectr 12:11-4. 2007
  89. ncbi request reprint Rivastigmine in dementia associated with Parkinson's disease and Alzheimer's disease: similarities and differences
    Murat Emre
    Department of Neurology, Istanbul Faculty of Medicine, Istanbul, Turkey
    J Alzheimers Dis 11:509-19. 2007
    ..In both populations, hallucinations may identify patients who are likely to be more treatment-responsive...
  90. ncbi request reprint The neuropsychiatric burden of neurological diseases in the elderly
    Jeffrey L Cummings
    Int Psychogeriatr 17:341-51. 2005
  91. ncbi request reprint Metabolic patterns associated with the clinical response to galantamine therapy: a fludeoxyglucose f 18 positron emission tomographic study
    Michael S Mega
    Alzheimers Disease Center and Center on Aging, Providence Health System, Portland, OR 97222
    Arch Neurol 62:721-8. 2005
    ..Regional brain correlates of treatment with cholinesterase inhibitors in those with Alzheimer disease are unknown...
  92. ncbi request reprint Mild cognitive impairment
    Serge Gauthier
    McGill Center for Studies in Aging, Douglas Hospital, Montreal, Quebec, Canada
    Lancet 367:1262-70. 2006
    ..Other definitions and subtypes of mild cognitive impairment need to be studied as potential prodromes of Alzheimer's disease and other types of dementia...
  93. ncbi request reprint Neuropsychiatric symptoms, functional impairment and executive ability in Thai patients with Alzheimer's disease
    Vorapun Senanarong
    Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand
    Int Psychogeriatr 17:81-90. 2005
    ..Planning and judgment are involved in clock drawing. Neuropsychiatric symptoms are also mediated by frontal lobes, and a relationship between ADL, clock drawing and neuropsychiatric symptoms was hypothesized...
  94. ncbi request reprint Neuropsychiatric symptoms and quality of life in Alzheimer disease
    Il Seon Shin
    Department of Psychiatry, Chonnam National University Medical School, Kwangju, Republic of Korea
    Am J Geriatr Psychiatry 13:469-74. 2005
    ..Authors examined the impact of neuropsychiatric symptoms in Alzheimer disease (AD) patients' and caregivers' quality of life (QOL) and assessed the relationship of caregiver distress to neuropsychiatric symptoms and caregiver QOL...
  95. ncbi request reprint Caregiver-Administered Neuropsychiatric Inventory (CGA-NPI)
    Sue J Kang
    Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Ilwon Dong Kangnam Ku, Seoul 135 710, South Korea
    J Geriatr Psychiatry Neurol 17:32-5. 2004
    ..6, P<.001). Total CGA-NPI scores also correlated highly with total NPI scores (r= 0.86, P<.001). These results suggest that the CGA-NPI can substitute for the NPI, saving administration time...
  96. ncbi request reprint The one-minute mental status examination
    Jeffrey L Cummings
    Neurology 62:534-5. 2004
  97. ncbi request reprint A new measurement of activities of daily living for Thai elderly with dementia
    Vorapun Senanarong
    Division of Neurology, Department of Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand
    Int Psychogeriatr 15:135-48. 2003
    ..We developed an ADL measure for Thai elderly with dementia and investigated the reliability and validity of this instrument...
  98. ncbi request reprint A collaborative study of the emergence and clinical features of the major depressive syndrome of Alzheimer's disease
    George S Zubenko
    Department of Psychiatry, Western Psychiatric Institute and Clinic, University of Pittsburgh School of Medicine, Room E1230, 3811 O Hara Street, Pittsburgh, PA 15213, USA
    Am J Psychiatry 160:857-66. 2003
    ....

Research Grants12

  1. IN VIVO CORRELATES OF NEUROPATHOLOGIC DIAGNOSIS IN ALZHEIMERS DISEASE
    Jeffrey Cummings; Fiscal Year: 1999
    ..2. To determine how Talairach coordinates predict anatomical lesion location. 3. To determine the spatial location of changes in the lesion over time. ..
  2. IN VIVO CORRELATES OF NEUROPATHOLOGIC DIAGNOSIS IN ALZHEIMERS DISEASE
    Jeffrey Cummings; Fiscal Year: 2002
    ..2. To determine how Talairach coordinates predict anatomical lesion location. 3. To determine the spatial location of changes in the lesion over time. ..
  3. IN VIVO CORRELATES OF NEUROPATHOLOGIC DIAGNOSIS IN ALZHEIMERS DISEASE
    Jeffrey Cummings; Fiscal Year: 2001
    ..2. To determine how Talairach coordinates predict anatomical lesion location. 3. To determine the spatial location of changes in the lesion over time. ..
  4. IN VIVO CORRELATES OF NEUROPATHOLOGIC DIAGNOSIS IN ALZHEIMERS DISEASE
    Jeffrey Cummings; Fiscal Year: 2001
    ..2. To determine how Talairach coordinates predict anatomical lesion location. 3. To determine the spatial location of changes in the lesion over time. ..
  5. IN VIVO CORRELATES OF NEUROPATHOLOGIC DIAGNOSIS IN ALZHEIMERS DISEASE
    Jeffrey Cummings; Fiscal Year: 2001
    ..2. To determine how Talairach coordinates predict anatomical lesion location. 3. To determine the spatial location of changes in the lesion over time. ..
  6. IN VIVO CORRELATES OF NEUROPATHOLOGIC DIAGNOSIS IN ALZHEIMERS DISEASE
    Jeffrey Cummings; Fiscal Year: 2000
    ..2. To determine how Talairach coordinates predict anatomical lesion location. 3. To determine the spatial location of changes in the lesion over time. ..